Plain-English translation of NCT07635277 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first study to test Akkermansia muciniphila (AKK), a naturally occurring helpful bacteria, applied directly to the skin to prevent radiation-induced skin injury. Radiation therapy for breast and head and neck cancer often damages the skin, causing painful burns and irritation in up to 85% of patients. Researchers believe this medication may reduce that damage by calming inflammation and helping the skin repair itself.
Most people getting radiation therapy for cancer develop significant skin damage, but current skin treatments don't work very well. This study exists to see if the medication can protect skin before and during radiation treatment, which could prevent painful burns and reduce suffering for thousands of cancer patients.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for screening and baseline skin assessment before treatment starts. During your radiation therapy (which may last 3–7 weeks depending on your cancer type), you'll apply the medication three times daily—once before your radiation session and twice at other times. You'll have weekly check-in visits where the study team examines your skin and takes photos. After your final radiation treatment, you'll return for follow-up visits at 2 weeks, 1 month, 2 months, and 3 months to see how your skin heals.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China